Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Université de Sherbrooke
With
Centre de recherche du CHU de Sherbrooke
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18-64 years
Diagnosis Long Covid based on WHO criteria (post-acute COVID-19 symptoms persisting ≥12 weeks) and validiated by an experienced cinician
Normal body Mass Index (18.5 to 39 kg/m2)
Able to communicate in and comprehend English and/or French language
Present written / signed declaration of consent
Ability to understand the patient information and willingness to sign the consent form
Willing to limit physical activity during prolonged fasting
You may not be if
Current underweight condition (body mass index less than 18.5 kg/m2) or weight loss exceeding 3 kg within the last month or 5 kg within the last three months.
Current or history of eating disorder (e.g., anorexia, bulimia).
Psychiatric condition that limits understanding of the examination protocol (unable to consent)
Participation in another intervention study.
Fasting during the last six months
Pregnancy or breastfeeding status.
Diagnosis of chronic inflammatory bowel diseases, celiac disease or colorectal cancer according to the guidelines of the Canadian Society of Gastroenterology
Use of anti-psychotic drugs
Start of novel drug therapy for long COVID
Contraindication for additional blood draws (e.g. hemoglobin \<100)
Taking opioid analgesics or undergoing treatment for opioid addiction
Opioid dependence or withdrawal syndrome
Type 1 or 2 Diabetes, or history of hypoglycemia
Active cancer
Baseline E+ (Na, K, Mg, phosphate) within normal range
Baseline ALT \< 60
Baseline Hb \> 100
Baseline INR within normal range
Baseline DFG \< 50
Clareo Health | A Fasting Pilot Study for Long COVID
